Hernandez Melissa J, Christman Karen L
Department of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California San Diego, La Jolla, CA, USA.
JACC Basic Transl Sci. 2017 Apr;2(2):212-226. doi: 10.1016/j.jacbts.2016.11.008. Epub 2017 Apr 24.
As the number of global deaths attributed to cardiovascular disease continues to rise, viable treatments for cardiovascular events such as myocardial infarction (MI) or conditions like peripheral artery disease (PAD) are critical. Recent studies investigating injectable biomaterials have shown promise in promoting tissue regeneration and functional improvement, and in some cases, incorporating other therapeutics further augments the beneficial effects of these biomaterials. In this review, we aim to emphasize the advantages of acellular injectable biomaterial-based therapies, specifically material-alone approaches or delivery of acellular biologics, in regards to manufacturability and the capacity of these biomaterials to regenerate or repair diseased tissue. We will focus on design parameters and mechanisms that maximize therapeutic efficacy, particularly, improved functional perfusion and neovascularization regarding PAD and improved cardiac function and reduced negative left ventricular (LV) remodeling post-MI. We will then discuss the rationale and challenges of designing new injectable biomaterial-based therapies for the clinic.
随着全球心血管疾病所致死亡人数持续上升,针对心肌梗死(MI)等心血管事件或外周动脉疾病(PAD)等病症的可行治疗方法至关重要。近期对可注射生物材料的研究已显示出在促进组织再生和功能改善方面的前景,在某些情况下,加入其他治疗剂可进一步增强这些生物材料的有益效果。在本综述中,我们旨在强调基于无细胞可注射生物材料的疗法的优势,特别是单独使用材料的方法或无细胞生物制剂的递送,涉及这些生物材料的可制造性以及再生或修复患病组织的能力。我们将专注于最大化治疗效果的设计参数和机制,特别是关于PAD的改善功能灌注和新血管形成,以及MI后改善心脏功能和减少左心室(LV)不良重塑。然后,我们将讨论为临床设计新型基于可注射生物材料的疗法的基本原理和挑战。